PDF(Pubmed)
Abstract：
Vitiligo is a skin depigmentation disease resulting from melanocyte destruction and often co-occurring with autoimmune disorders like hyperthyroidism, alopecia areata, pernicious anemia, and systemic lupus erythematosus (SLE). Although various traditional treatments exist for vitiligo, their effectiveness varies considerably. This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases.
摘要：
白癜风是一种由黑素细胞破坏引起的皮肤色素脱失疾病，通常与甲状腺功能亢进等自身免疫性疾病同时发生，斑秃,恶性贫血,和系统性红斑狼疮（SLE）。尽管白癜风存在各种传统治疗方法，它们的有效性差异很大。本报告介绍了一例伴有系统性红斑狼疮的白癜风患者的独特病例。值得注意的是,在使用托法替尼治疗30天的疗程后，实现了白色黄斑皮疹的完全色素沉着,无药物不良反应。这些发现为口服JAK抑制剂的有效性和安全性提供了令人信服的证据。如托法替尼，在白癜风治疗中。此外,JAK抑制剂仍可被视为并发自身免疫性疾病的白癜风患者的有希望的新治疗选择。
